DiaMedica Therapeutics In...

NASDAQ: DMAC · Real-Time Price · USD
6.03
0.02 (0.33%)
At close: Aug 15, 2025, 3:59 PM
6.03
0.08%
After-hours: Aug 15, 2025, 04:10 PM EDT

DiaMedica Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
n/a n/a 13.8M n/a n/a n/a 30.84M n/a n/a n/a n/a 76K 13K n/a n/a n/a n/a n/a
Cost of Revenue
3K 11K n/a 6.88M 10K 8K 8K 5.16M 4.74M 5.52M 6K 3.13M 3.36M 3.54M 6K 3.42M 3.37M 3.62M
Gross Profit
-3K -11K 6.9M -6.88M -10K -8K -8K -5.16M -4.74M -5.52M -6K -3.05M -3.35M -3.54M -6K -3.42M -3.37M -3.62M
Operating Income
-8.01M -8.14M -8.42M -6.88M -5.64M -5.74M -5.85M -10.31M -4.74M -5.52M -3.97M -3.13M -3.36M -3.54M -3.25M -3.42M -3.37M -3.62M
Interest Income
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 353K n/a n/a 35K n/a n/a n/a 4K
Pretax Income
-7.69M -7.7M -7.89M -6.27M -5.11M -5.14M -5.14M -4.46M -4.47M -5.26M -3.74M -3.05M -3.35M -3.5M -3.24M -3.44M -3.27M -3.62M
Net Income
-7.7M -7.71M -7.9M -6.27M -5.12M -5.15M -5.16M -4.47M -4.48M -5.27M -3.75M -3.06M -3.36M -3.51M -3.25M -3.45M -3.27M -3.62M
Selling & General & Admin
2.18M 2.49M 1.95M 1.9M 1.71M 2.06M 2.16M 1.89M 2.2M 1.9M 1.7M 1.49M 1.41M 1.56M 1.38M 1.08M 1.21M 1.21M
Research & Development
5.82M 5.66M 6.47M 4.98M 3.93M 3.68M 3.68M 3.27M 2.54M 3.62M 2.27M 1.64M 1.96M 1.97M 1.87M 2.33M 2.16M 2.41M
Other Expenses
n/a n/a n/a n/a n/a n/a n/a n/a 271K 256K n/a 76K 13K 35K 7K -27K 98K 4K
Operating Expenses
8M 8.14M 8.42M 6.88M 5.64M 5.74M 5.84M 5.16M 4.74M 5.52M 3.97M 3.13M 3.36M 3.54M 3.25M 3.42M 3.37M 3.62M
Interest Expense
n/a n/a n/a n/a n/a n/a 5.76M n/a n/a n/a 159K n/a n/a 35K n/a n/a n/a n/a
Selling & Marketing Expenses
n/a n/a n/a n/a n/a n/a -8K n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
8.01M 8.14M 8.42M 6.88M 5.64M 5.74M 5.85M 5.16M 4.74M 5.52M 3.97M 3.13M 3.36M 3.54M 3.25M 3.42M 3.37M 3.62M
Income Tax Expense
6K 6K 9K 7K 7K 7K 22K 7K 7K 7K 7K 7K 7K 7K 7K 7K 7K 7K
Shares Outstanding (Basic)
42.96M 42.84M 42.82M 42.75M 38.07M 37.96M 37.96M 37.95M 27.31M 26.45M 26.44M 26.44M 26.44M 26.44M 19.04M 19.04M 18.79M 18.77M
Shares Outstanding (Diluted)
42.96M 42.84M 42.82M 42.75M 38.07M 37.96M 37.96M 37.95M 27.31M 26.45M 26.44M 26.44M 26.44M 26.44M 19.04M 19.04M 18.79M 18.77M
EPS (Basic)
-0.18 -0.18 -0.18 -0.15 -0.13 -0.14 -0.14 -0.12 -0.16 -0.2 -0.14 -0.12 -0.13 -0.13 -0.17 -0.18 -0.17 -0.19
EPS (Diluted)
-0.18 -0.18 -0.18 -0.15 -0.13 -0.14 -0.14 -0.12 -0.16 -0.2 -0.14 -0.12 -0.13 -0.13 -0.17 -0.18 -0.17 -0.19
EBITDA
-7.69M -8.13M -8.41M -6.87M -5.63M -5.73M -5.84M -5.15M -4.73M -5.51M -3.97M -3.12M -3.36M -3.53M -3.24M -3.41M -3.36M -3.61M
EBIT
-7.69M -8.14M -8.42M -6.88M -5.64M -5.74M -5.85M -5.16M -4.74M -5.52M -3.97M -3.13M -3.36M -3.54M -3.25M -3.42M -3.37M -3.62M
Depreciation & Amortization
3K 11K 11K 10K 10K 8K 8K 8K 24K 24K 6K 7K 6K 6K 6K 6K 6K 6K